Clarence Carnot Evans, Jr, MD: A statesman for dermatology - 28/02/18
Doi : 10.1016/j.jaad.2017.10.020
Seymour Rand, MD a, John J. DiGiovanna, MD b, ⁎ 
, Howard I. Maibach, MD c, Rebat Halder, MD d, Jonathan K. Wilkin, MD e, Maria L. Chanco Turner, MD f, Lynn A. Drake, MD g, John J. Voorhees, MD h
, Howard I. Maibach, MD c, Rebat Halder, MD d, Jonathan K. Wilkin, MD e, Maria L. Chanco Turner, MD f, Lynn A. Drake, MD g, John J. Voorhees, MD h a private practice, Hummelstown, Pennsylvania
b Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
c University of California Medical School, San Francisco, California
d Department of Dermatology, Howard University College of Medicine, Washington, DC
e retired, Columbus and Grand Cayman
f Dermatology Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
g Harvard Medical School, Boston, Massachusetts
h Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan
∗Correspondence to: John J. DiGiovanna, MD, DNA Repair Section, Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Dr, Room 4002, Bethesda, MD 20892-4262.DNA Repair Section, Laboratory of Cancer Biology and GeneticsCenter for Cancer ResearchNational Cancer InstituteNational Institutes of Health37 Convent Dr, Room 4002BethesdaMD20892-4262
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
© 2017
Vol 78 - N° 3
P. e77-e78 - mars 2018 Retour au numéro
Article précédent
- Reply to: “Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials”
- Mark Lebwohl
- Iotaderma #289
- Robert I. Rudolph
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?